• Adefovir (GS-0393) Research Workflow

  2026-09-19

  Build reproducible HBV antiviral and OAT1 transporter assays with Adefovir, using distinct workflows for viral DNA polymerase inhibition and renal secretion profiling. Practical preparation, exposure, structural-biology, and troubleshooting guidance helps separate compound handling problems from genuine biological effects.

• Lanabecestat (AZD3293) in BACE1 Research

  2026-09-18

  Lanabecestat (AZD3293) enables controlled BACE1 enzyme inhibition while pairing amyloid-beta measurements with functional synaptic readouts. This workflow guide translates the reference study into practical concentration design, assay controls, and troubleshooting strategies for Alzheimer's disease research.

• NET-DNA–CCDC25 Axis in Intestinal Repair

  2026-09-18

  A 2026 FASEB Journal study identifies NET-derived DNA as an inhibitor of ILC3-mediated intestinal repair in ulcerative colitis models. The work connects NET-DNA sensing through CCDC25 to reduced IL-22 production, impaired epithelial barrier restoration, and a downstream ILK–HIF-1α signaling axis.

• MK-0812 in Gut–Liver Inflammation Assays

  2026-09-17

  MK-0812 enables mechanistic testing of CCR2-dependent monocyte recruitment in gut–liver inflammation. This article shows how to use its pharmacology to distinguish intestinal trigger, circulating-cell trafficking, and hepatic inflammatory response in MASH research.

• Octyl-α-ketoglutarate: HIF-1α Assay Logic

  2026-09-17

  Explore how Octyl-α-ketoglutarate functions as a prolyl hydroxylase substrate for separating α-KG limitation from oxygen-driven HIF-1α stabilization. This article connects intracellular substrate delivery with IDH1/IDH2 and TCA cycle dysfunction research while emphasizing rigorous assay interpretation.

• Valemetostat: From EZH2 Biology to Assay Design

  2026-09-16

  Valemetostat and DS-3201 offer a precise route to interrogate EZH2-driven lymphoma biology. This article connects mutant-aware pharmacology with a cross-domain lesson from metabolic research: robust translational conclusions require layered, orthogonal assays rather than a single endpoint.

• Cisapride (R 51619) in Cardiac Electrophysiology

  2026-09-16

  Cisapride (R 51619) is a dual-action research tool for connecting 5-HT4 receptor signaling with hERG-related cardiac liabilities. Combined with iPSC-derived cardiomyocytes, high-content imaging, and orthogonal electrophysiology, it helps build practical workflows for cardiac arrhythmia research and early safety profiling.

• Separating Growth Arrest from Cell Death in Cancer

  2026-09-15

  Schwartz’s 2022 dissertation shows that relative viability and fractional viability capture different components of anticancer response: proliferative arrest and cell death. Its paired-endpoint, time-aware framework helps cancer biology researchers interpret drug screens more rigorously and avoid treating growth inhibition as a direct surrogate for killing.

• UBR1 and UBR2 in ER Stress Protein Quality Control

  2026-09-15

  The reference study identifies the N-recognins UBR1 and UBR2 as stress-responsive components of mammalian protein quality control. Its genetic, stability, and ubiquitination analyses show that these E3 ligases become more stable during ER stress and help protect cells from stress-induced apoptosis, expanding current models of ER-associated degradation.

• Capsaicin Workflows for TRPV1 and KDM1A Research

  2026-09-14

  Capsaicin is a versatile tool for connecting TRPV1 ion channel activation with sensory-neuron behavior, chronic dermatitis, and pain biology. Its separate KDM1A/LSD1 activity also supports mechanistic cancer assays when formulation, exposure window, and vehicle controls are carefully matched.

• AZ505: From SMYD2 Binding to Causal Biology

  2026-09-14

  AZ505 is a selective SMYD2 inhibitor for connecting substrate methylation with fibrosis, inflammation, and cancer phenotypes. This article presents a causal assay framework grounded in renal disease research rather than repeating conventional product or handling guidance.

• Cell Counting Kit-8 Assay: Workflow & Troubleshooting

  2026-09-13

  Build a more reliable CCK8 workflow for proliferation, viability, and cytotoxicity studies with water-soluble WST-8 chemistry. This guide translates a macrophage–lung cancer study into practical controls, plate layouts, optimization steps, and interpretation safeguards.

• Central Opioid Control of Mechanical OIH

  2026-09-12

  A 2024 Neuron study identifies a lateral parabrachial–hypothalamic–spinal opioid pathway that regulates morphine-induced mechanical hypersensitivity and analgesic tolerance in mice. Its findings separate mechanical pain phenotypes from better-established thermal mechanisms and provide a circuit framework for opioid receptor signaling research, while pharmacological KOR studies remain complementary rather than direct replications of the reported experiments.

• Perifosine (KRX-0401): From Akt Biology to Translation

  2026-09-11

  A mechanistic and translational guide to using Perifosine as an Akt pathway probe across apoptosis, combination oncology, and carefully bounded neuroprotection research.

• SMYD2 Inhibition in Cisplatin-Induced Renal Fibrosis

  2026-09-11

  The reference study identifies SMYD2 as a pharmacologically actionable regulator of cisplatin-induced chronic kidney disease, linking its inhibition with reduced renal fibrosis, inflammation, and epithelial–mesenchymal transition. Evidence from animal and tubular epithelial-cell models supports Smad3- and STAT3-related signaling as mechanisms that may connect SMYD2 activity to fibrogenic kidney injury.

8509 records 1/568 page Next 12345 下5页 Last page